NCT00841113View on ClinicalTrials.gov

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

February 28, 2001

Study Completion Date

February 28, 2003

Conditions
Prostate Cancer
Interventions
DRUG

Abarelix

100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter

DRUG

Goserelin plus Bicalutamide

Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months

All Listed Sponsors
lead

Speciality European Pharma Limited

INDUSTRY

NCT00841113 - Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter